Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 5/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857080 | 0.83 | DYRK1A (0.59) | DYRK1AKCNH2CNR1GSK3BNFATC1 | |
| SCHEMBL4858853 | 0.75 | DYRK1A (0.57) | DYRK1AKCNH2GSK3BPIK3CA | |
| SCHEMBL4857617 | 0.73 | NFATC1 (0.61) | DYRK1ACNR1CNR2GSK3BNFATC1 | |
| SCHEMBL2468525 | 0.72 | DYRK1A (0.50) | DYRK1AKCNH2CNR1CNR2GSK3B | |
| SCHEMBL31165814 | 0.72 | DYRK1A (0.67) | DYRK1AKCNH2GSK3BNFATC1 | |
| SCHEMBL4859713 | 0.72 | DYRK1A (0.67) | DYRK1AKCNH2GSK3BNFATC1 | |
| SCHEMBL4855717 | 0.70 | DYRK1A (0.43) | DYRK1AKCNH2CNR1CNR2GSK3B | |
| SCHEMBL4851580 | 0.70 | CHEK1 (0.48) | DYRK1AKCNH2CNR1CNR2GSK3B | |
| SCHEMBL18256602 | 0.69 | PARG (0.46) | NAMPTPIK3CA | |
| SCHEMBL19117804 | 0.69 | DYRK1A (0.66) | DYRK1AKCNH2GSK3BNFATC1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | DYRK1A 1117/4885KCNH2 2535/4885CNR1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.